Copyright
©The Author(s) 2021.
World J Gastroenterol. Jun 28, 2021; 27(24): 3643-3653
Published online Jun 28, 2021. doi: 10.3748/wjg.v27.i24.3643
Published online Jun 28, 2021. doi: 10.3748/wjg.v27.i24.3643
Table 1 Inclusion and exclusion criteria for administration of darvadstrocel
Inclusion | Exclusion |
Complex anal fistulas associated with Crohn’s disease (including horse-shoe fistula) | Simple fistulas associated with Crohn’s disease, rectovaginal fistula |
At least one conventional, biological or surgical therapy prior to stem cell injection | No medical, biological or surgical therapy prior to stem cell injection |
No active Crohn’s disease confirmed by ileocolonoscopy | Active Crohn’s disease confirmed by ileocolonoscopy |
No perianal abscess or sepsis confirmed by clinical exam, endoanal ultrasound and/or pelvic MRI | Perianal abscess or significant inflammation in the pelvis or anorectal region confirmed by MRI |
Interdisciplinary recommendation | No recommendation by multidisciplinary team |
Patient compliant for medical consultation, follow-up examination and interdisciplinary monitoring of disease | Non-compliance of patient |
Pretreatment of fistulas by seton drainage (“conditioning”) | Fistulas without seton drainage or conditioning by curettage |
Maximum of two fistulas with two internal and two external openings (each) | More than two complex fistulas |
No anorectal stenosis | Presence of anorectal stenosis |
Fully informed consent possible | No informed consent possible |
- Citation: Schwandner O. Stem cell injection for complex anal fistula in Crohn’s disease: A single-center experience. World J Gastroenterol 2021; 27(24): 3643-3653
- URL: https://www.wjgnet.com/1007-9327/full/v27/i24/3643.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i24.3643